Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vβ repertoire

Cancer

Volumn 106, Issue 6, 2006, Pages 1296-1305

  Péres Andres, Martin ^a   Almeida, Julia ^a   Martin Ayuso, Marta ^a   Moro, Maria Jesus ^b   Martin Nuñez, Guillermo ^c   Galende, Josefina ^d   Hernandez, Jose ^e   Mateo, Gema ^a,f   San Miguel, Jesus F ^a,f   Orfao, Alberto ^a,g  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Hospital Virgen Blanca   (Spain)

^c HOSPITAL VIRGEN DEL PUERTO   (Spain)

^d HOSPITAL EL BIERZO   (Spain)

^e HOSPITAL GENERAL DE SEGOVIA   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g Centro de Investigacion del Cancer   (Spain)

Author keywords

Bone marrow microenvironment; Immune response; Immunophenotype; Monoclonal garamopathy; T cell; TCR V repertoire

Indexed keywords

T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR V BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE MARROW CELL; CANCER PATIENT; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LYMPHOCYTIC INFILTRATION; MALE; MICROENVIRONMENT; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

AGED; ANTIGENS, CD; BONE MARROW CELLS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; LEUKEMIA, PLASMACYTIC; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 33644847914     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21746     Document Type: Article

References (45)

1. Kyle RA. The monoclonal gammopathies. Clin Chem. 1994; 40:2154-2161.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
3. Kyle RA. Monoclonal gammopathies of undetermined significance. Baillieres Clin Haematol. 1995;8:761-781.
4. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152:1655-1664.
5. Sezer O, Heider U, Zarski I, Possinger K. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica, 2001;86:837-843.
6. Costello R, Sainty D, Bouabdallah R, et al. Primary plasma cell leukemia: a report of 18 cases. Leuk Res. 2001;25:103-107.
7. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037.
8. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
9. Ghia P, Granziero L, Chilosi M, Caligaris-Cappio F. Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol. 2002;12:149-155.
10. Raitakari M, Brown RD, Gibson J, Joshua DE. T cells in myeloma. Hematol Oncol. 2003;21:33-42.
11. Moss P, Gillespie G, Frodsham P, Bell J, Reybrun H. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood. 1996;8:3297-3306.
12. Brown RD, Yuen E, Nelson M, Gibson J, Joshua DE. The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia. 1997;11:1312-1317.
13. Sze DM, Giesajtis G, Brown RD, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood. 2001;98:2817-2827.
14. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony P, Wilheim M. Stimulation of gammadelta T cells by aminophosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384-392.
15. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
16. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003;102:1435-1442.
17. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998;6:597-603.
18. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanism. Leukemia. 2003;17:1175-1182.
19. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA. 2002;99:13009-13013.
20. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003;11:1753-1757.
21. Lim SH, Badros A, Lue C, Bartologie N. Distinct T-cell clonal expansions in the vicinity of tumor cells in plasmacytoma. Cancer. 2001;91:900-908.
22. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280-3285.
23. Szea DM, Brown RD, Yang S, et al. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leuk Lymph. 2003;44:1557-1568.
24. Garcia-Sanz R, Gonzalez M, Orfao A, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol. 1996;93:81-88.
25. Almeida J, Bueno C, Alguero MC, et al. Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage- cells. Clin Exp Immunol. 1999;118:392-401.
26. Osterborg A, Nilsson B, Bjorkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol. 1990;45:153-157.
27. King MA, Radicchi-Mastrioanni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry. 1996;26:121-124.
28. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
29. Borthwick NJ, Lowdell M, Salmon M, Akbar AN. Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol. 2000;12:1005-1013.
30. Appay V. The physiological role of cytotoxic CD4+ T-cells: the holy grail? Clin Exp Immunol 2004;138:10-13.
31. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641-648.
32. Ikeda H, Chamoto K, Tsuji T, et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004;95:697-703.
33. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
34. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2:293-299.
35. Huang H, Liu Y, Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral Interferon γ-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 2002;217:12-22.
36. Zhang X, Xhen Z, Huang H, Gordon JR, Xiang J. DNA microarray analysis of the gene expression profiles of naive versus activated tumor-specific T cells. Life Sci. 2002;71:3005-3017.
37. Schuler T, Blankstein T. CD8+ effector cells reject tumors by direct antigen recognition by indirect action on host cells. J Immunol. 2003;170:4427-4431.
38. Owagara H, Handa H, Yamazaki T, et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res. 2005;29:135-140.
39. Di Rosa F, Santoni A. Bone marrow CD8 T cells are in different activation state than those in lymphoid periphery. Eur J Immunol. 2002;32:1873-1880.
40. Price PW, Cerny J. Characterization of CD4+ T cells in mouse bone marrow. I. Increased activated/memory phenotype and altered TCR Vbeta repertoire. Eur J Immunol. 1999;29:1051-1056.
41. Moteiro JP, Benjamin A, Costa ES, Barcinski MA, Bonomo A. Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells. Blood. 2005;105:1484-1491.
42. Porakishvili N, Kardava L, Jewell AP, et al. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via perforin-mediated pathway. Haematologica. 2004;89:435-443.
43. null T cells clonally expanded in rheumatoid arthritis. J Immunol. 2000;165:1138-1145.
44. van Bergen J, Thompson A, van der Slik A, Ottenhoff TH, Gussekloo J, Koning F. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol. 2004;173:6719-6726.
45. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med. 2005;201:1025-1029.